E V McCloskey

Summary

Affiliation: University of Sheffield
Country: UK

Publications

  1. ncbi Effects of third-generation aromatase inhibitors on bone
    Eugene McCloskey
    Academic Unit of Bone Metabolism, Metabolic Bone Centre, Northern General Hospital, Sorby Wing, Herries Road, Sheffield S5 7AU, UK
    Eur J Cancer 42:1044-51. 2006
  2. doi FRAX updates 2012
    Eugene McCloskey
    Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK
    Curr Opin Rheumatol 24:554-60. 2012
  3. doi Fracture risk assessment
    Eugene McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
    Clin Biochem 45:887-93. 2012
  4. doi Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX
    Eugene V McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom
    J Bone Miner Res 27:1480-6. 2012
  5. ncbi Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women
    Eugene V McCloskey
    Academic Unit of Bone Metabolism, University of Sheffield, Sorby Wing, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK
    Eur J Cancer 43:2523-31. 2007
  6. ncbi Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study
    Eugene McCloskey
    Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom
    J Bone Miner Res 19:728-36. 2004
  7. doi Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study
    E V McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
    Osteoporos Int 20:811-7. 2009
  8. doi Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosis
    Eugene V McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom
    J Bone Miner Res 23:1561-8. 2008
  9. ncbi Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study
    Eugene V McCloskey
    Northern General Hospital, Sheffield, UK
    J Bone Miner Res 22:135-41. 2007
  10. doi Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer
    Eugene McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Eur J Cancer 46:558-65. 2010

Detail Information

Publications51

  1. ncbi Effects of third-generation aromatase inhibitors on bone
    Eugene McCloskey
    Academic Unit of Bone Metabolism, Metabolic Bone Centre, Northern General Hospital, Sorby Wing, Herries Road, Sheffield S5 7AU, UK
    Eur J Cancer 42:1044-51. 2006
    ....
  2. doi FRAX updates 2012
    Eugene McCloskey
    Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK
    Curr Opin Rheumatol 24:554-60. 2012
    ..This brief review addresses the development of FRAX since then and describes some of the issues that continue to be discussed as FRAX plays an increasing role in clinical practice...
  3. doi Fracture risk assessment
    Eugene McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
    Clin Biochem 45:887-93. 2012
    ..Notwithstanding, the present models provide an aid to enhance patient assessment by the integration of clinical risk factors alone and/or in combination with BMD...
  4. doi Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX
    Eugene V McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom
    J Bone Miner Res 27:1480-6. 2012
    ..Denosumab significantly decreased the risk of clinical osteoporotic fractures in postmenopausal women. Overall, the efficacy of denosumab was greater in those at moderate to high risk of fracture as assessed by FRAX...
  5. ncbi Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women
    Eugene V McCloskey
    Academic Unit of Bone Metabolism, University of Sheffield, Sorby Wing, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK
    Eur J Cancer 43:2523-31. 2007
    ..Further, long-term clinical studies are required to determine the impact, if any, of the differences observed between the AIs..
  6. ncbi Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study
    Eugene McCloskey
    Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom
    J Bone Miner Res 19:728-36. 2004
    ..The incidence of vertebral fractures was significantly reduced by 46%. The effect was not modified by the underlying cause of osteoporosis or other baseline factors including bone mineral density, QUS, weight, and smoking...
  7. doi Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study
    E V McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
    Osteoporos Int 20:811-7. 2009
    ..This study demonstrates that the estimation of an individual's 10-year probability of fracture by the FRAX algorithm identifies patients at high risk of fracture who will respond to bisphosphonate therapy...
  8. doi Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosis
    Eugene V McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom
    J Bone Miner Res 23:1561-8. 2008
    ..Having multiple vertebral fractures was associated with greater risk of incident osteoporotic fractures and hip fractures...
  9. ncbi Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study
    Eugene V McCloskey
    Northern General Hospital, Sheffield, UK
    J Bone Miner Res 22:135-41. 2007
    ..The effect occurred in the absence of systematic calcium and vitamin D supplementation and was observed across a wide range of BMDs...
  10. doi Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer
    Eugene McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Eur J Cancer 46:558-65. 2010
    ..This study shows the use of oral clodronate during primary breast cancer treatment is associated with reduced bone turnover and protection against bone metastases...
  11. doi FRAX(®) Clinical Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference
    Eugene V McCloskey
    University of Sheffield, Sheffield, UK
    J Clin Densitom 14:181-3. 2011
    ..This synthesis was presented to the expert panel and constitutes the data on which the subsequent Official Positions are predicated. A summary of the Clinical Task Force composition and charge is presented here...
  12. doi Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®
    Eugene V McCloskey
    Academic Unit of Bone Metabolism, University of Sheffield, Sheffield S5 7AU, UK
    J Clin Densitom 14:220-2. 2011
    ..More research is clearly required to address these deficiencies before biochemical markers might contribute a useful independent risk factor for inclusion in FRAX(®)...
  13. ncbi The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma
    E V McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, England
    Drugs 61:1253-74. 2001
    ..It is not known whether more potent bisphosphonates will deliver greater clinical efficacy in the future...
  14. pmc A high incidence of vertebral fracture in women with breast cancer
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK
    Br J Cancer 79:1179-81. 1999
    ..3-9.9], and 20-fold higher in women with soft-tissue metastases without evidence of skeletal metastases (OR, 22.7; 95% CI, 9.1-57.1). We conclude that vertebral fracture risk is markedly increased in women with breast cancer...
  15. ncbi A family history of fracture and fracture risk: a meta-analysis
    J A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Sheffield, UK
    Bone 35:1029-37. 2004
    ..Its identification on an international basis supports the use of this risk factor in case-finding strategies...
  16. doi Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 19:1395-408. 2008
    ..Assessment and intervention thresholds are developed and proposed in men aged over 50 years and postmenopausal women for the UK based on fracture probability from the WHO fracture risk assessment tool (FRAX)...
  17. doi Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate
    K Kayan
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK
    Osteoporos Int 20:2055-61. 2009
    ..Fall risk does not significantly impact on the efficacy of the bisphosphonate clodronate in reducing the incidence of fracture...
  18. ncbi A meta-analysis of previous fracture and subsequent fracture risk
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Bone 35:375-82. 2004
    ..Its validation on an international basis permits the use of this risk factor in case finding strategies...
  19. pmc European guidance for the diagnosis and management of osteoporosis in postmenopausal women
    J A Kanis
    WHO Collaborating Centre, UK University of Sheffield Medical School, Sheffield, UK
    Osteoporos Int 24:23-57. 2013
    ..Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk of fractures due to osteoporosis...
  20. doi Development and use of FRAX in osteoporosis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 21:S407-13. 2010
    ..The FRAX tool integrates information on fracture risk from clinical risk factors with or without the use of BMD and can be used to improve the targeting of individuals at high fracture risk...
  21. doi Guidance for the adjustment of FRAX according to the dose of glucocorticoids
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S102RX, UK
    Osteoporos Int 22:809-16. 2011
    ..A relatively simple adjustment of conventional FRAX estimates of probabilities of hip fracture and a major osteoporotic fracture can be applied to modulate the risk assessment with knowledge of the dose of glucocorticoids...
  22. doi The effects of a FRAX revision for the USA
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Osteoporos Int 21:35-40. 2010
    ..With the revised tool, there were strong correlations (r > 0.99) between versions 2.0 and 3.0 for FRAX estimates of fracture probability, but the revised models gave lower probability estimates...
  23. pmc SCOPE: a scorecard for osteoporosis in Europe
    J A Kanis
    University of Sheffield Medical School, Sheffield, UK
    Arch Osteoporos 8:144. 2013
    ..The resulting scorecard elements were then assembled on a single sheet to provide a unique overview of osteoporosis in Europe...
  24. pmc A systematic review of hip fracture incidence and probability of fracture worldwide
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK
    Osteoporos Int 23:2239-56. 2012
    ..There was a greater than 10-fold variation in hip fracture risk and fracture probability between countries...
  25. doi Interpretation and use of FRAX in clinical practice
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 22:2395-411. 2011
    ..Its use in fracture risk prediction has strengths, but also limitations of which the clinician should be aware and are the focus of this review..
  26. doi Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican Institute of Social Security
    H Johansson
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 22:2359-64. 2011
    ..If the age-specific incidence of hip fracture continues, the number of hip fractures would increase by a further 46%...
  27. ncbi Studies of bone density, quantitative ultrasound, and vertebral fractures in relation to collagen type I alpha 1 alleles in elderly women
    R U Ashford
    The WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, England
    Calcif Tissue Int 68:348-51. 2001
    ..We conclude that COLIA1 Sp1 alleles are not significantly associated with BMD, ultrasound properties of bone, or fractures in this population-based sample of elderly women...
  28. pmc Performance of clinical referral criteria for bone densitometry in patients under 65 years of age assessed by spine bone mineral density
    K Kayan
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
    Postgrad Med J 79:581-4. 2003
    ..A case finding strategy based on a number of established risk factors has been suggested by Royal College of Physicians' (RCP) guidelines to optimise bone densitometry referrals for assessment of osteoporosis...
  29. ncbi Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma
    E V McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Medical School, Sheffield, UK
    Br J Haematol 113:1035-43. 2001
    ..These observations, however, require confirmation in prospective clinical trials...
  30. ncbi Smoking and fracture risk: a meta-analysis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 16:155-62. 2005
    ..Its validation on an international basis permits the use of this risk factor in case finding strategies...
  31. ncbi Atypical familial Paget's disease of bone
    K C Pande
    WHO Collaborating Centre for Metabolic Bone Diseases, Royal Hallamshire Hospital, Sheffield, UK
    Joint Bone Spine 68:257-61. 2001
    ..We report unusual clinical and radiological features of Paget's disease of bone in three family members. All three patients had satisfactory biochemical and symptomatic response to treatment with an intravenous bisphosphonate (clodronate)...
  32. doi How to decide who to treat
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK
    Best Pract Res Clin Rheumatol 23:711-26. 2009
    ..The tool increases sensitivity without trading specificity and is now being used in the re-appraisal of clinical guidelines...
  33. ncbi Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK
    Health Technol Assess 11:iii-iv, ix-xi, 1-231. 2007
    ..To determine whether strategies can be devised for the assessment and treatment of glucocorticoid-induced osteoporosis (GIO)...
  34. doi A FRAX® model for the assessment of fracture probability in Belgium
    H Johansson
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 22:453-61. 2011
    ..A country-specific FRAX® model was developed from the epidemiology of fracture and death in Belgium. Fracture probabilities were identified that corresponded to currently accepted reimbursement thresholds...
  35. pmc Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate)
    E V McCloskey
    Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, UK
    Br J Cancer 69:914-7. 1994
    ..We conclude that aminohexane bisphosphonate is an effective agent in the treatment of tumour-induced hypercalcaemia, with rapid onset of effect and low toxicity...
  36. doi A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®)
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, South Yorkshire, UK
    Osteoporos Int 22:2347-55. 2011
    ..Hazard ratios for the effect of strontium ranelate on the fracture outcome did not change significantly with increasing fracture probability...
  37. doi Worldwide uptake of FRAX
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Arch Osteoporos 9:166. 2014
    ..The worldwide uptake of FRAX is described...
  38. doi Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures
    H Johansson
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 25:235-41. 2014
    ..In this meta-analysis of the control arms of four phase 3 trials, mild vertebral fractures were a significant risk factor for future vertebral fractures but not for non-vertebral fracture...
  39. pmc Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate
    E V McCloskey
    Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, UK
    Br J Cancer 67:560-3. 1993
    ..The single infusion has a more rapid onset of effect, is more convenient than multiple infusions, and has no adverse effect on renal function...
  40. ncbi Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension
    Caroline Brumsen
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, The Netherlands
    J Bone Miner Res 17:1057-64. 2002
    ..One hundred fifty milligrams daily of pamidronate is an effective and safe treatment of women and men with established osteoporosis...
  41. ncbi Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis
    Steven Boonen
    Leuven University Center for Metabolic Bone Diseases and Division of Geriatric Medicine, Universitaire Ziekenhuizen, K U Leuven, Herestraat 49, B 3000 Leuven, Belgium
    J Clin Endocrinol Metab 93:852-60. 2008
    ..The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr...
  42. doi Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer
    Trevor J Powles
    Breast Unit, Parkside Oncology Clinic, Wimbledon, London, UK
    Menopause Int 14:6-12. 2008
    ....
  43. doi Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group
    David M Reid
    Department of Rheumatology, University of Aberdeen, United Kingdom
    Cancer Treat Rev 34:S3-18. 2008
    ..Management recommendations have been summarised in two algorithms, one for women experiencing a premature menopause and the other for postmenopausal women requiring adjuvant aromatase inhibitor therapy...
  44. doi A reference standard for the description of osteoporosis
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK
    Bone 42:467-75. 2008
    ..5 SD or more below the average for young adult women. The adoption of DXA as a reference standard provides a platform on which the performance characteristics of less well established and new methodologies can be compared...
  45. ncbi Abdominal aortic calcification detected on lateral spine images from a bone densitometer predicts incident myocardial infarction or stroke in older women
    John T Schousboe
    Park Nicollet Health Services, Minneapolis, Minnesota 55416, USA
    J Bone Miner Res 23:409-16. 2008
    ....
  46. ncbi Risk factors for incident vertebral fractures in men and women: the Rotterdam Study
    Marjolein van der Klift
    Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
    J Bone Miner Res 19:1172-80. 2004
    ..In 3001 men and women from the Rotterdam Study, prevalent nonvertebral fractures, early menopause, current smoking, and walking aid use were also strong risk factors for incident vertebral fractures...
  47. ncbi Optimization of BMD measurements to identify high risk groups for treatment--a test analysis
    Helena Johansson
    Statistician, Romelanda, Sweden
    J Bone Miner Res 19:906-13. 2004
    ..Baseline assessment included hip BMD and clinical risk factors. Outcomes included death and fracture in women followed for 6723 person-years...
  48. ncbi The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study
    Edit Toth
    Department of Rheumatology, Flór Ferenc Country Hospital, Kistarcsa, H 2143, Hungary
    Bone 36:47-51. 2005
    ..We conclude that 200 IU salmon calcitonin nasal spray used daily, intermittently proved to be an effective and safe therapy in male idiopathic osteoporosis...
  49. ncbi The incidence of vertebral fractures in men and women: the Rotterdam Study
    Marjolein van der Klift
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Bone Miner Res 17:1051-6. 2002
    ..In both genders, the incidence increases with age. Furthermore, the presence of a prevalent vertebral fracture and a low BMD are strong independent predictors of incident vertebral fractures in men and women...
  50. ncbi Case-finding for adult celiac disease in patients with reduced bone mineral density
    David S Sanders
    Royal Hallamshire Hospital, Sheffield, UK
    Dig Dis Sci 50:587-92. 2005
    ..However, a targeted case-finding approach may be more valid and cost-effective with the initial selection of patients who should be investigated for CD based on questioning about gastrointestinal symptoms or anemia...
  51. ncbi A primary care cross-sectional study of undiagnosed adult coeliac disease
    David S Sanders
    Gastroenterology and Liver Unit, Royal Hallamshire Hospital, Sheffield, UK
    Eur J Gastroenterol Hepatol 15:407-13. 2003
    ..To establish the prevalence of coeliac disease in the general population and in specific conditions, such as irritable bowel syndrome, iron deficiency anaemia, fatigue and other coeliac-related conditions...